Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25321059 | 1.00 | MEN1 (0.41) | MEN1KMT2AGRIN2BSLC18A3SIGMAR1 | |
| SCHEMBL25323286 | 0.81 | NOS3 (0.35) | MEN1KMT2AGRIN2BKDM4E | |
| SCHEMBL6924404 | 0.80 | MEN1 (0.47) | MEN1KMT2ASLC18A3SIGMAR1SMN1; SMN2 | |
| SCHEMBL14065400 | 0.80 | MEN1 (0.47) | MEN1KMT2ASLC18A3SIGMAR1SMN1; SMN2 | |
| SCHEMBL4865057 | 0.80 | MEN1 (0.47) | MEN1KMT2ASLC18A3SIGMAR1SMN1; SMN2 | |
| SCHEMBL11468464 | 0.74 | MEN1 (0.45) | MEN1KMT2ASLC18A3SIGMAR1SMN1; SMN2 | |
| SCHEMBL22039441 | 0.73 | KCNH2 (0.43) | ALDH1A1KDM4E | |
| SCHEMBL24367529 | 0.72 | TSHR (0.46) | MEN1KMT2ASLC18A3SIGMAR1SMN1; SMN2 | |
| SCHEMBL25322414 | 0.72 | TSHR (0.46) | MEN1KMT2ASLC18A3SIGMAR1SMN1; SMN2 | |
| SCHEMBL25322420 | 0.72 | TSHR (0.46) | MEN1KMT2ASLC18A3SIGMAR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | MEN1 164/4885KMT2A 2453/4885GRIN2B 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.